Viracta Therapeutics to Participate at H.C. Wainwright Global Life Sciences Conference

Rhea-AI Summary

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company, announced its participation in the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. A pre-recorded presentation will be available on-demand via the conference portal starting at 7 a.m. ET on March 9. The management team will also host one-on-one investor meetings. Viracta focuses on treating virus-associated malignancies with its investigational drug, nanatinostat, currently in a Phase 2 trial for EBV-positive lymphoma.

SAN DIEGO, March 3, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that Viracta will participate at the H.C. Wainwright Global Life Sciences Conference, being held March 9-10, 2021. A pre-recorded presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7 a.m. ET on March 9, 2021. Viracta's management team will also be available for one-on-one investor meetings at the conference.

About Viracta Therapeutics, Inc.

Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphoma. Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.

For additional information please visit www.viracta.com.

Investor Relations Contact:	Company Contact:
Joyce Allaire	Dan Chevallard
LifeSci Advisors	Chief Financial Officer
jallaire@lifesciadvisors.com	dchevallard@viracta.com
(212) 915-2569	(858) 771-4193

 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/viracta-therapeutics-to-participate-at-hc-wainwright-global-life-sciences-conference-301239433.html

SOURCE Viracta

FAQ

What is Viracta Therapeutics participating in on March 9-10, 2021?

Viracta Therapeutics is participating in the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021.

When will Viracta's presentation be available at the conference?

The pre-recorded presentation by Viracta will be available on-demand starting at 7 a.m. ET on March 9, 2021.

What is the focus of Viracta Therapeutics?

Viracta Therapeutics focuses on precision oncology, targeting virus-associated malignancies.

What is Viracta's investigational drug?

Viracta's investigational drug is nanatinostat, which is in a Phase 2 clinical trial for EBV-positive lymphoma.

What cancers are being targeted by Viracta's drug combination?

Viracta is targeting EBV-positive lymphoma and other virus-related cancers, including nasopharyngeal and gastric carcinoma.